Cai C, Chen JM, Qiu ZX, Ren SQ. Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies. World J Clin Oncol 2026; 17(2): 116390 [DOI: 10.5306/wjco.v17.i2.116390]
Corresponding Author of This Article
Shu-Qi Ren, Associate Research Scientist, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, No. 10 Dexiu Road, Zhongshan 528467, Guangdong Province, China. shuchijen@163.com
Research Domain of This Article
Oncology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Feb 24, 2026 (publication date) through Feb 12, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Cai C, Chen JM, Qiu ZX, Ren SQ. Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies. World J Clin Oncol 2026; 17(2): 116390 [DOI: 10.5306/wjco.v17.i2.116390]
World J Clin Oncol. Feb 24, 2026; 17(2): 116390 Published online Feb 24, 2026. doi: 10.5306/wjco.v17.i2.116390
Role of claudin-6 in high-grade endometrial carcinoma: Implications for risk stratification and personalized treatment strategies
Chuang Cai, Jin-Man Chen, Zu-Xun Qiu, Shu-Qi Ren
Chuang Cai, Department of Cancer Research Institute of Zhongshan, Zhongshan People’s Hospital, Zhongshan 528445, Guangdong Province, China
Jin-Man Chen, Department of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, Guangdong Province, China
Zu-Xun Qiu, Shu-Qi Ren, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, Zhongshan 528467, Guangdong Province, China
Co-first authors: Chuang Cai and Jin-Man Chen.
Author contributions: Cai C and Chen JM contributed to the work equally and are co-first authors of this manuscript; Cai C and Chen JM conceived the review and drafted the initial manuscript; Cai C, Chen JM, Qiu ZX, and Ren SQ made substantial contributions to this manuscript; Chen JM and Qiu ZX were responsible for literature collation; Cai C and Ren SQ edited and finalized the manuscript for submission; and all authors reviewed and approved the submitted manuscript.
Supported by Zhongshan Science and Technology Bureau, No. 2023B1033.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shu-Qi Ren, Associate Research Scientist, Department of Laboratory Medicine, Zhongshan Integrated Traditional Chinese and Western Medicine Hospital, No. 10 Dexiu Road, Zhongshan 528467, Guangdong Province, China. shuchijen@163.com
Received: November 11, 2025 Revised: December 1, 2025 Accepted: December 24, 2025 Published online: February 24, 2026 Processing time: 87 Days and 24 Hours
Abstract
This commentary discusses the groundbreaking study by Ebrahim et al on the role of claudin-6 (CLDN6) in high-grade endometrial carcinoma, addressing a significant gap in current knowledge. Their research reveals that overexpression of CLDN6 is linked to unfavorable pathological features. Moreover, multivariate analysis establishes CLDN6 as an independent predictor of disease-free survival, with a hazard ratio of 68.98. These results highlight the promise of CLDN6 in improving risk stratification and as a potential therapeutic target, especially with the development of CLDN6-directed antibody-drug conjugates. To advance CLDN6 towards clinical application, further validation in prospective patient cohorts and studies exploring its interactions with other molecular pathways are essential.
Core Tip: This editorial focuses on the expression and clinical importance of the tight junction protein claudin-6 (CLDN6) in high-grade endometrial carcinoma. It demonstrates that CLDN6 overexpression independently correlates with aggressive pathological characteristics and poor patient outcomes. These findings underscore CLDN6’s value as a prognostic biomarker and highlight its potential as a therapeutic target, opening new possibilities for improved risk stratification and personalized treatment strategies in high-grade endometrial carcinoma.
